戻る Agenda
Session 1: Landscape and Emerging Innovations within Clinical Trials
Session Chair(s)
Rui (Sammi) Tang
Vice President, Global Head of Biometrics
Servier Pharmaceuticals, United States
Veronica Bubb, DBA, PHD, MS
Vice President of Operations
Advance Research Associates, Inc., United States
In modern drug development, organizations are implementing innovative clinical trial designs with the intention of optimizing the speed of product development and maximizing the potential for cost savings while simultaneously maintaining the probability of success of their clinical trials. In line with the vision to stimulate innovation in drug development, this session invites renowned speakers that promote innovation in clinical trials to enhance productivity and agility in investigational product development.
Learning Objective : - Discuss the current innovative landscape in clinical trials
- Identify innovative trial designs motivated by a real-world application to simultaneously evaluate multiple drugs in multiple indications
- Explore case examples of using RWD in clinical trial design and discuss its operational constraints
- Describe innovative approaches taken during the collection and analysis of COVID-19 data to allow for real-time decision-making
Speaker(s)
Landscape and Emerging Innovations within Clinical Trials: Dose Optimization
Ying Yuan, PHD
University of Texas MD Anderson Cancer Center, United States
Bettyann Asche Murray Distinguished Professor
Innovative Clinical Trial Design: How can we best leverage real-world data?
Keri Monda, PHD, MS
Amgen, United States
Executive Director, Center for Observational Research
Innovative Clinical Trial Design: How can we best leverage real-world data?
Veronica Bubb, DBA, PHD, MS
Advance Research Associates, Inc., United States
Vice President of Operations
Potential estimands and estimators for trials impacted by COVID-19
Kelly Van Lancker, DRSC
Ghent University, Belgium
Postdoctoral Research Fellow